18.11.2025 07:30:00 CET | Thor Medical ASA | Non-regulatory press releases

Oslo, 18 November 2025 - Thor Medical ASA today announces the appointment of
Therese Kvehaugen and Mathias Nilsen Reierth to the executive management team,
two key additions as the company accelerates its growth journey to become a
global leader in the sustainable supply of alpha isotopes for targeted cancer
therapies.

Therese Kvehaugen will join Thor Medical as Executive Vice President, Human
Resources, effective January 12, 2026, while Mathias Nilsen Reierth will take on
the role of Head of Communications and Corporate Affairs no later than February
1, 2026. Both will report directly to CEO Jasper Kurth and become members of the
company's executive management team.

"We have high ambitions at Thor Medical and are building an organization capable
of driving meaningful impact for cancer patients, customers and partners, and
society at large. Strengthening our leadership team with exceptional people like
Therese and Mathias is an important step on that journey," said Jasper Kurth,
CEO of Thor Medical.

"Mathias combines strategic communications expertise with a strong understanding
of advanced technology and industrial innovation, while Therese brings deep
international HR experience from the biotechnology industry and a proven ability
to scale high-performing, advanced organizations. Together, they will help
transition Thor Medical from a pioneering phase to a key industrial-scale
supplier in targeted cancer therapies," Kurth added.

Therese Kvehaugen joins Thor Medical from Timbr, a strategic HR advisory having
served as CEO. Prior to that, she served as Head of HR at Nykode Therapeutics
and she spent several years with Alnylam Pharmaceuticals in Switzerland, helping
the company grow from a small pre-commercial biotech to a global Ribonucleic
Acid therapeutics leader. Earlier in her career, she held HR leadership roles
with Rambøll, Biogen and Franke.

Mathias Nilsen Reierth brings extensive experience in communications, corporate
affairs, and strategy from leadership roles in the green industry and energy
sector at Vow Green Metals, Aker Horizons, and Hafslund. He also has a
background as a journalist with leading Norwegian media, including TV 2, Dagens
Næringsliv, and Verdens Gang, as well as experience from management consulting.

CONTACTS

Jasper Kurth, CEO, Thor Medical ASA, jasper.kurth@thormedical.com

ABOUT THOR MEDICAL ASA 

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle
emitters, from naturally occurring thorium. Its proprietary production process
requires no irradiation or use of nuclear reactors, and provides reliable,
environmentally friendly, cost-efficient supply of alpha-emitters for the
radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'. To learn
more, visitwww.thormedical.com - http://visitwww.thormedical.com - 
https://www.thormedical.com.

ATTACHMENTS

Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18723171/6583/Download%20announce
ment%20as%20PDF.pdf